External quality assessment (EQA) for tumor mutational burden: results of an international IQN path feasibility pilot scheme Tumor mutational burden (TMB) has recently been approved as an agnostic biomarker for immune checkpoint inhibitors. However, methods for TMB testing have not yet been standardized. The International Quality Network for Pathology (IQNPath) organized a pilot external quality read more…